Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxycodone
Drug ID BADD_D01645
Description Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917.[A178696] It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.[L6460]
Indications and Usage For the treatment of diarrhoea, pulmonary oedema and for the relief of moderate to moderately severe pain.
Marketing Status Prescription; Discontinued
ATC Code N02AA05
DrugBank ID DB00497
KEGG ID D05312
MeSH ID D010098
PubChem ID 5284603
TTD Drug ID D07WPQ
NDC Product Code 68071-5055; 0904-7180; 65162-047; 24510-115; 24510-130; 67651-0304; 65162-050; 71335-1023; 67651-0306; 67651-0305; 71335-0981; 24510-140; 71335-1080; 65162-051; 24510-120; 65162-048; 67877-625; 71335-0677; 65162-049; 67651-0303; 24510-110; 67877-623; 0904-6966; 67651-0302
Synonyms Oxycodone | Dihydrone | Oxycone | Dihydrohydroxycodeinone | Oxycodeinon | Eucodal | Theocodin | Oxycodone Hydrochloride | Oxycontin | Pancodine | Dinarkon | Oxiconum
Chemical Information
Molecular Formula C18H21NO4
CAS Registry Number 76-42-6
SMILES CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Regurgitation07.01.07.004--Not Available
Post procedural infection12.02.05.010; 11.01.08.0190.000093%Not Available
Brain injury19.07.03.007; 17.11.01.0030.000109%Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Post procedural constipation12.02.03.014; 07.02.02.016--Not Available
Acute kidney injury20.01.03.0160.001253%
Spinal column injury15.02.04.014; 12.01.09.0060.000093%Not Available
Hypoxic-ischaemic encephalopathy24.04.06.021; 22.02.02.011; 17.13.02.0060.000048%Not Available
Lacrimal structural disorder06.06.04.013--Not Available
Hepatic cancer16.07.02.004; 09.04.02.0080.000024%Not Available
Medication residue present13.15.01.0320.001393%Not Available
Cardiovascular symptom24.03.02.025; 02.01.02.0150.000232%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000206%
Anal incontinence17.05.01.021; 07.01.06.0290.000093%
Depersonalisation/derealisation disorder19.14.01.004--Not Available
Lung carcinoma cell type unspecified stage IV16.19.02.006; 22.08.01.0190.000048%Not Available
Metastases to bone16.22.02.005; 15.09.03.0060.000024%Not Available
Nasal necrosis22.04.03.0200.000093%Not Available
Patella fracture15.08.03.015; 12.04.01.0150.000093%Not Available
Persecutory delusion19.10.01.0070.000093%Not Available
Pupil fixed17.02.11.008; 06.05.03.0120.000139%Not Available
Slow response to stimuli17.02.05.0630.000093%Not Available
Throat cancer22.08.02.008; 16.19.02.0070.000186%Not Available
Neonatal hypotension24.06.03.014; 18.04.07.0080.000093%Not Available
Live birth18.08.02.0070.000093%Not Available
Spinal cord ischaemia24.04.06.040; 17.10.01.0180.000139%Not Available
Clostridium difficile infection11.02.02.0090.000093%Not Available
Biliary dilatation09.02.03.0040.000139%Not Available
Multi-organ disorder08.01.03.0740.000024%Not Available
Troponin T increased13.04.01.0150.000186%
The 22th Page    First    Pre   22 23    Next   Last    Total 23 Pages